WO2021238834A1 - Composé arylformamide et son procédé de préparation et son utilisation médicale - Google Patents

Composé arylformamide et son procédé de préparation et son utilisation médicale Download PDF

Info

Publication number
WO2021238834A1
WO2021238834A1 PCT/CN2021/095424 CN2021095424W WO2021238834A1 WO 2021238834 A1 WO2021238834 A1 WO 2021238834A1 CN 2021095424 W CN2021095424 W CN 2021095424W WO 2021238834 A1 WO2021238834 A1 WO 2021238834A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
alkoxy
cycloalkyl
halogen
Prior art date
Application number
PCT/CN2021/095424
Other languages
English (en)
Chinese (zh)
Inventor
殷惠军
闫旭
宗利斌
刘国标
张守良
陈彬
Original Assignee
中国医药研究开发中心有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国医药研究开发中心有限公司 filed Critical 中国医药研究开发中心有限公司
Priority to AU2021282039A priority Critical patent/AU2021282039A1/en
Priority to CN202180004411.6A priority patent/CN114072399A/zh
Publication of WO2021238834A1 publication Critical patent/WO2021238834A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the invention belongs to the technical field of medicine, and specifically relates to an arylformamide compound, a preparation method thereof, and a pharmaceutical composition containing the same, and its use as a P2X3 receptor antagonist in the treatment and/or prevention of diseases related to P2X3 activity use.
  • ATP can drive and regulate various sensory behaviors and related responses.
  • ATP can drive and regulate various sensory behaviors and related responses.
  • ATP has a greater impact on sensation.
  • P2X3 is the main receptor that mediates the sensory effects of ATP.
  • the P2X3 receptor is an ATP-gated cation channel and belongs to the P2X receptor family.
  • the P2X receptor family also includes P2X1, P2X2, P2X4, P2X5, P2X6, and P2X7.
  • P2X3 acts in the body in the form of homotrimer P2X3 or heterotrimer P2X2/3 (NeuroReport, 10, 1107-1111).
  • P2X3 and P2X2/3 are mainly expressed in the small and medium diameter C- and A ⁇ -fiber sensory neurons in the dorsal root ganglia (DRG) and cranial sensory ganglia, as well as peripheral nerve endings in the receptive fields of skin, joints and internal organs.
  • DRG dorsal root ganglia
  • cranial sensory ganglia peripheral nerve endings in the receptive fields of skin, joints and internal organs.
  • the P2X3 receptor is a member of the purinergic receptor family. It is a non-selective ligand-gated ion channel. After ATP activates it, it allows Na + , K + , and Ca 2+ to pass, especially Ca 2+ .
  • the permeability is the most obvious, and it plays an important role in the generation and transmission of harmful information.
  • PKA protein kinase A
  • PKC Protein kinase C
  • P2X3 receptors play an important role in the process of nociception. For example, P2X3 receptor knockout significantly reduces the pain response. P2X3 receptor antagonists have antineoplastic effects in various models of pain and inflammatory pain. In addition to its prominent role in nociception and acute and chronic pain, P2X3 receptors have also been shown to be involved in the pathological process of genitourinary system, gastrointestinal and respiratory diseases, especially overactive bladder and chronic cough. Therefore, P2X3 receptors play an important role in the pathological mechanisms of various diseases including pain, genitourinary system diseases, gastrointestinal diseases and respiratory diseases, and are ideal targets for the treatment of these diseases.
  • the P2X3 subunit not only forms a homotrimer, but also a heterotrimer with a P2X2 subunit.
  • the P2X3 and P2X2 subunits are also expressed on the nerve fibers of the tongue, and receptors containing the P2X3 and/or P2X2 subunits participate in taste transmission (bitter, sweet, salty, umami and sour).
  • Studies have shown that P2X3 homotrimers are mainly involved in mediating nociception, while P2X2/X3 heterotrimers are mainly involved in taste perception.
  • Knockout animals lacking P2X2 and P2X3 subunits exhibit reduced taste and even loss of taste, while P2X3 subunit knockouts exhibit mild or no changes in phenotype (J. Physiol. 2015, 593, 1113–1125).
  • P2X3 receptor antagonists the compound Gefapixant (AF-219) developed by Merck and Afferent (PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE OF THE UNITED STATES OF AMERICA, 115(19), 4939-4944 .), the compound is a non-selective antagonist of P2X3 and P2X2/X3, and has shown significant efficacy in the clinical phase II study for chronic cough, but it also shows the side effects of taste interference. This side effect is mainly due to P2X2/3 heterotrimer blockade. Therefore, there is a continuing need for new or improved P2X3 antagonists for the development of new and more effective drugs to treat chronic cough or other diseases related to P2X3.
  • the object of the present invention is to provide a compound represented by the general formula (I) or its meso, racemate, enantiomer, diastereomer, or mixture form thereof, or Its medicinal salt,
  • W 1 , W 2 , and W 3 are each independently selected from CR 6 or N;
  • a 1 , A 2 , A 3 , A 4 , and A 5 are each independently selected from C, N, O or S;
  • R 1 is selected from -NR a R b , -NR a S(O) m R b , -NR a S(O) m NR a R b , -NR a S(O)(NR a )R b , -NR a S(O)(NR a )NR b , -NR a C(O)R b , -NR a C(O)NR a R b , -S(O) m R a , -S(O) m NR a R b , -S(O)(NR a )NR a R b , -OR a , -C(O)NR a R b , -P(O)R a R b , -(CR a R b )R b ;
  • Each R 2 is independently selected from hydrogen, halogen, amino, nitro, cyano, hydroxyl, mercapto, oxo, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl , -C(O)R a , -O(O)CR a , -C(O)OR a , -C(O)NR a R b , -NHC(O)R a , -S(O) m R a, -S (O) m NR a R b, -NHS (O) m R a; wherein said alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl groups are optionally further substituted Selected from halogen, amino, nitro, cyano, oxo, hydroxyl, mercapto, carboxy, ester, alkyl, alkoxy, alkenyl, alkyn
  • R 3 is selected from aryl or heteroaryl; the aryl or heteroaryl is optionally further substituted with one or more groups selected from halogen, alkyl, haloalkyl, alkoxy, and haloalkoxy;
  • L is selected from -C(R 4 R 5 )-;
  • R 4 and R 5 are each independently selected from hydrogen, alkyl, alkoxy; wherein the alkyl and alkoxy are optionally further selected from halogen, amino, nitro, cyano, hydroxyl, mercapto, carboxy, One or more group substitutions of ester group, oxo group, alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group;
  • R 6 is selected from hydrogen, halogen, hydroxyl, cyano, amino, carboxy, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein The alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group are optionally further selected from halogen, amino, nitro, cyano, hydroxyl, mercapto, carboxyl, One or more group substitutions of ester group, oxo group, alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group;
  • R a and R b are each independently selected from hydrogen, halogen, hydroxyl, cyano, amino, carboxy, ester, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, Heteroaryl groups, wherein the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl groups are optionally further selected from halogen, amino, nitro, cyano, One of hydroxyl, mercapto, carboxyl, ester, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroaryl or one of Multiple group substitutions;
  • R a and R b together with the atoms to which they are attached form a cycloalkyl or heterocyclic group the cycloalkyl or heterocyclic group is optionally further selected from halogen, amino, nitro, cyano, oxo, One or more groups of hydroxyl, mercapto, carboxyl, ester, alkyl, alkoxy, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl replace;
  • n 0, 1 or 2;
  • n is an integer from 0 to 3.
  • the compound represented by the general formula (I) according to the present invention or its mesomer, racemate, enantiomer, diastereomer, Or a mixture thereof, or a pharmaceutically acceptable salt thereof which is a compound represented by the general formula (II) or a meso, racemate, enantiomer, diastereomer, or In the form of a mixture, or a pharmaceutically acceptable salt thereof,
  • a 1 , A 2 , A 3 , A 4 , A 5 , R 1 , R 2 , R 3 , L, and n are as defined in the general formula (I).
  • R 2 and n are as defined in the general formula (I).
  • R 3 is a C 6 -C 10 aryl group or a 5- to 10-membered heteroaryl group, preferably phenyl, pyridyl, pyrimidiny
  • R 1 is selected from -NR a R b , -NR a S(O) m R b , -NR a S(O) m NR a R b , -NR a S(O)(NR a )R b , -NR a S(O)(NR a )NR b , -NR a C(O)R b , -NR a C(O)NR a R b , -S(O) m R a , -S(O) m NR a R b , -S(O)(NR a )NR a R b , -OR a , -C(O)NR a R b , -P(O)R a R b , -(CR a R b )R b , preferably -NR a R b , -NR a S(O) 2 R b , -NR
  • R a and R b are each independently selected from hydrogen, halogen, alkyl, alkoxy, cycloalkyl, and heterocyclyl, wherein the alkyl, alkoxy, cycloalkyl, and heterocyclyl are optionally further selected from Selected from halogen, amino, nitro, cyano, hydroxyl, mercapto, carboxy, ester, oxo, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, hetero One or more aryl groups are substituted;
  • R a and R b together with the atoms to which they are attached form a 5- to 8-membered heterocyclic group the heterocyclic group is optionally further selected from halogen, amino, nitro, cyano, oxo, hydroxyl, mercapto, One or more group substitutions of carboxyl group, ester group, alkyl group, alkoxy group, alkenyl group, alkynyl group, cycloalkyl group, heterocyclic group, aryl group and heteroaryl group;
  • n 0, 1, or 2.
  • R 1 is selected from -NR a R b ;
  • R a is selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 5-8 membered heterocyclyl particularly oxygen Etanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, wherein the C 1 -C 6 alkyl, C 3 -C 6 ring Alkyl and 5-8 membered heterocyclic groups are optionally further selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy One or more groups of the group are substituted;
  • R b is selected from hydrogen or C 1 -C 6 alkyl.
  • R 1 is selected from -NR a R b ;
  • R a and R b together with the nitrogen atom to which they are attached form a 5- to 8-membered heterocyclic group, preferably tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, or 8-membered spiro heterocyclic group;
  • the cyclic group is optionally further selected from one or more groups selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy replace.
  • R 1 is selected -S (O) R a, or -SO 2 R a;
  • R a is selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 5-8 membered heterocyclyl particularly oxygen Etanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, wherein the C 1 -C 6 alkyl, C 3 -C 6 ring Alkyl and 5-8 membered heterocyclic groups are optionally further selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy One or more groups of the group are substituted.
  • R 1 is selected from -S(O) 2 NR a R b ;
  • R a is selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 5-8 membered heterocyclyl particularly oxygen Etanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, wherein the C 1 -C 6 alkyl, C 3 -C 6 ring Alkyl and 5-8 membered heterocyclic groups are optionally further selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy One or more groups of the group are substituted;
  • R b is selected from hydrogen or C 1 -C 6 alkyl
  • R a and R b together with the nitrogen atom to which they are attached form a 5- to 8-membered heterocyclic group, preferably tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, or 8-membered spiro heterocyclic group;
  • the heterocyclic group is optionally further selected from one or more of halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy Group substitution.
  • R 1 is selected from -OR a ;
  • R a is selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 5-8 membered heterocyclyl particularly oxygen Etanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, wherein the C 1 -C 6 alkyl, C 3 -C 6 ring Alkyl and 5-8 membered heterocyclic groups are optionally further selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy One or more groups of the group are substituted.
  • R 1 is selected from -P(O)R a R b ;
  • R a is selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or 5-8 membered heterocyclyl particularly oxygen Etanyl, azetidinyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, wherein the C 1 -C 6 alkyl, C 3 -C 6 ring Alkyl and 5-8 membered heterocyclic groups are optionally further selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy One or more groups of the group are substituted;
  • R b is selected from hydrogen or C 1 -C 6 alkyl
  • R a and R b together with the atoms to which they are attached form a 5- to 8-membered heterocyclic group, especially a phosphoryl group;
  • the heterocyclic group is optionally further selected from halogen, C 1 -C 6 alkyl, One or more groups of C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, and C 1 -C 6 haloalkoxy are substituted.
  • R 2 is selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 7 cycloalkyl, 5- to 7-membered heterocyclic group; preferably C 1 -C 6 alkyl ; Wherein the alkyl group, alkoxy group, cycloalkyl group, heterocyclic group are optionally further selected from halogen, amino, nitro, cyano, oxo, hydroxyl, mercapto, carboxyl, ester, alkyl, One or more groups of alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are substituted.
  • L is selected from -C(R 4 R 5 )-;
  • R 4 and R 5 are each independently selected from hydrogen, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy.
  • Typical compounds of the present invention include but are not limited to:
  • the present invention further provides a method for preparing the compound represented by the general formula (I) according to the present invention or its meso, racemate, enantiomer, diastereomer, or mixture thereof Form, its prodrug or its pharmaceutically acceptable salt method, which comprises the following steps:
  • the compound Ig and Ih are subjected to a condensation reaction under basic conditions to obtain a compound of general formula (I), wherein the basic condition is preferably DIPEA, and the condensing agent is preferably HATU;
  • W 1 , W 2 , W 3 , A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , R 2 , R 3 , L, and n are as defined in the general formula (I).
  • Another aspect of the present invention provides a pharmaceutical composition, which contains the compound represented by the general formula (I) according to the present invention or its mesomer, racemate, enantiomer, or diastereomer Isomers, or mixtures thereof, prodrugs or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable carriers.
  • the present invention further provides the compound represented by the general formula (I) according to the present invention or its mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, and Use of a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the prodrug in the preparation of a P2X3 antagonist.
  • the present invention further provides the compound represented by the general formula (I) according to the present invention or its mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, and Use of a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the prodrug in the preparation of a medicine for preventing and/or treating diseases related to P2X3 activity.
  • the present invention further provides the compound represented by the general formula (I) according to the present invention or its mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, and A prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the prodrug, for use as a P2X3 antagonist.
  • the present invention further provides the compound represented by the general formula (I) according to the present invention or its mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, and A prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing it, for use as a medicine for the prevention and/or treatment of diseases related to P2X3 activity.
  • the present invention further provides a method for preventing and/or treating diseases associated with P2X3 activity, which comprises administering to a subject in need a preventive or therapeutically effective amount of the compound represented by the general formula (I) of the present invention
  • a preventive or therapeutically effective amount of the compound represented by the general formula (I) of the present invention The compound or its mesosome, racemate, enantiomer, diastereomer, or mixture thereof, its prodrug or its pharmaceutically acceptable salt, or a pharmaceutical composition containing it.
  • the diseases related to P2X3 activity according to the present invention may be: respiratory diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, pulmonary fibrosis, acute cough, Chronic cough, including chronic idiopathic and chronic refractory cough, genitourinary system, gastrointestinal, respiratory and pain-related diseases, gynecological diseases including dysmenorrhea (primary and secondary dysmenorrhea), dyspareunia, dysuria or Orchitis, endometriosis and adenomyosis, endometriosis-related pain, endometriosis-related symptoms, pelvic hypersensitivity, urinary tract disease state related to bladder outlet obstruction, urinary incontinence Symptoms such as decreased bladder capacity, increased urination frequency, urge incontinence, stress urinary incontinence or overreaction of the bladder, benign prostatic hypertrophy, prostatic hyperplasia, prostatitis,
  • respiratory diseases including chronic ob
  • IBS irritable bowel syndrome
  • IBD inflammatory bowel disease
  • biliary colic and other biliary diseases renal colic
  • diarrhea Predominant IBS, gastroesophageal reflux, gastrointestinal dilatation, Crohn’s disease
  • neurodegenerative diseases such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, cerebral ischemia and traumatic brain injury, Myocardial infarction, lipid disorders, pain-related diseases or conditions are selected from hyperalgesia, allodynia, functional bowel disease, gout, arthritis (such as osteoarthritis, rheumatoid arthritis and ankylosing spondylitis), Burning mouth syndrome, burns, migraine or cluster headache, nerve injury, post-traumatic injury (including fractures and sports injuries), neuritis, neuralgia, poisoning, ischemic injury, interstitial cystitis, cancer, trigeminal Neuralgia, small fiber neuropathy,
  • the compound represented by the general formula (I) of the present invention can form a pharmaceutically acceptable acid addition salt with an acid.
  • the acid includes inorganic acid and organic acid, particularly preferably hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene disulfonic acid, acetic acid, propionic acid, lactic acid , Trifluoroacetic acid, maleic acid, citric acid, fumaric acid, oxalic acid, tartaric acid, benzoic acid, etc.
  • the compound represented by the general formula (I) of the present invention can form a pharmaceutically acceptable basic addition salt with a base.
  • the base includes inorganic bases and organic bases.
  • Acceptable organic bases include diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, etc.
  • acceptable inorganic bases include aluminum hydroxide, hydroxide Calcium, potassium hydroxide, sodium carbonate and sodium hydroxide, etc.
  • the present invention also includes prodrugs of the compounds represented by the general formula (I) of the present invention.
  • the prodrugs of the present invention are derivatives of the compound represented by the general formula (I). They may have weak or even no activity by themselves, but after administration, under physiological conditions (for example, through metabolism, solvolysis) Or another way) is converted into the corresponding biologically active form.
  • the pharmaceutical composition containing the active ingredient may be in a form suitable for oral administration, such as tablets, dragees, lozenges, water or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or Elixirs.
  • Oral compositions can be prepared according to any method known in the art for preparing pharmaceutical compositions, and such compositions can contain one or more ingredients selected from the group consisting of sweeteners, flavoring agents, coloring agents and preservatives, To provide pleasing and delicious medicinal preparations.
  • the tablet contains the active ingredient and non-toxic pharmaceutically acceptable excipients suitable for the preparation of tablets for mixing.
  • excipients can be inert excipients, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as microcrystalline cellulose, croscarmellose sodium, corn Starch or alginic acid; binders, such as starch, gelatin, polyvinylpyrrolidone, or gum arabic; and lubricants, such as magnesium stearate, stearic acid, or talc.
  • These tablets may be uncoated or may be coated by known techniques that mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained release effect over a longer period of time.
  • water-soluble taste-masking substances such as hydroxypropyl methylcellulose or hydroxypropyl cellulose, or extended time substances such as ethyl cellulose, cellulose acetate butyrate may be used.
  • Hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin can also be used, or in which the active ingredient is mixed with a water-soluble carrier such as polyethylene glycol or an oil solvent such as peanut oil, liquid paraffin or olive oil.
  • Soft gelatin capsules provide oral preparations.
  • Aqueous suspensions contain the active substance and excipients suitable for the preparation of aqueous suspensions for mixing.
  • excipients are suspending agents, such as sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, sodium alginate, polyvinylpyrrolidone and gum arabic; dispersing or wetting agents, which can be natural Produced phospholipids such as lecithin, or condensation products of alkylene oxides and fatty acids, such as polyoxyethylene stearate, or condensation products of ethylene oxide and long-chain fatty alcohols, such as seventeen-carbon ethyleneoxy whale Heptadecaethyleneoxy cetanol, or condensation products of ethylene oxide and partial esters derived from fatty acids and hexitols, such as polyethylene oxide sorbitol monooleate, or ethylene oxide with fatty acids and hexitols Condensation products of anhydride-derived partial esters, such as polyethylene oxide sorbitan monooleate
  • the aqueous suspension may also contain one or more preservatives such as ethyl paraben or n-propyl paraben, one or more coloring agents, one or more flavoring agents and one or more sweeteners.
  • preservatives such as ethyl paraben or n-propyl paraben
  • coloring agents such as ethyl paraben or n-propyl paraben
  • flavoring agents such as sucrose, saccharin or aspartame.
  • Oil suspensions can be formulated by suspending the active ingredients in vegetable oils such as peanut oil, olive oil, sesame oil or coconut oil, or mineral oils such as liquid paraffin. Oil suspensions may contain thickeners such as beeswax, hard paraffin or cetyl alcohol. The above-mentioned sweeteners and flavoring agents can be added to provide a palatable preparation. These compositions can be preserved by adding antioxidants such as butylated hydroxyanisole or alpha-tocopherol.
  • dispersible powders and granules suitable for preparing aqueous suspensions can provide the active ingredient and a dispersing or wetting agent for mixing, a suspending agent or one or more preservatives. Suitable dispersing or wetting agents and suspending agents are as described above. Other excipients such as sweeteners, flavoring agents and coloring agents may also be added. These compositions are preserved by adding antioxidants such as ascorbic acid.
  • the pharmaceutical composition of the present invention may also be in the form of an oil-in-water emulsion.
  • the oil phase can be a vegetable oil such as olive oil or peanut oil, or a mineral oil such as liquid paraffin or a mixture thereof.
  • Suitable emulsifiers can be naturally occurring phospholipids, such as soybean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation of the partial esters and ethylene oxide Products such as polyethylene oxide sorbitol monooleate.
  • the emulsion may also contain sweetening agents, flavoring agents, preservatives and antioxidants.
  • Syrups and elixirs formulated with sweetening agents such as glycerin, propylene glycol, sorbitol or sucrose.
  • Such preparations may also contain a demulcent, a preservative, a coloring agent and an antioxidant.
  • the pharmaceutical composition of the present invention may be in the form of a sterile injectable aqueous solution.
  • Acceptable solvents and solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution.
  • the sterile injectable preparation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in the oil phase.
  • the active ingredient is dissolved in a mixture of soybean oil and lecithin.
  • the oil solution is added to the mixture of water and glycerin to form a microemulsion.
  • the injection or microemulsion can be injected into the patient's bloodstream by local large-scale injection. Alternatively, it is best to administer the solution and microemulsion in a manner that maintains a constant circulating concentration of the compound of the present invention. To maintain this constant concentration, a continuous intravenous delivery device can be used.
  • the pharmaceutical composition of the present invention may be in the form of a sterile injection water or oil suspension for intramuscular and subcutaneous administration.
  • the suspension can be formulated according to known techniques using those suitable dispersing or wetting agents and suspending agents mentioned above.
  • the sterile injection preparation may also be a sterile injection solution or suspension prepared in a non-toxic parenterally acceptable diluent or solvent, for example, a solution prepared in 1,3-butanediol.
  • sterile fixed oil can be conveniently used as a solvent or suspension medium. For this purpose, any blended fixed oil including synthetic mono- or diglycerides can be used.
  • fatty acids such as oleic acid can also be used to prepare injections.
  • the compounds of the present invention can be administered in the form of suppositories for rectal administration.
  • These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid in the rectum and thus will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, polyethylene glycols of various molecular weights, and mixtures of fatty acid esters of polyethylene glycol.
  • the dosage of drugs depends on many factors, including but not limited to the following factors: the activity of the specific compound used, the patient’s age, the patient’s weight, the patient’s health, the patient’s clothing, and the patient’s The diet, time of administration, mode of administration, rate of excretion, combination of drugs, etc.
  • the best treatment method such as the treatment mode, the daily dosage of the compound of the general formula, or the type of pharmaceutically acceptable salt can be verified according to the traditional treatment plan.
  • the present invention may contain a compound represented by general formula (I), and a pharmaceutically acceptable salt, hydrate or solvate thereof as an active ingredient, mixed with a pharmaceutically acceptable carrier or excipient to prepare a composition, and Prepared into a clinically acceptable dosage form.
  • the derivatives of the present invention can be used in combination with other active ingredients as long as they do not produce other adverse effects, such as allergic reactions and the like.
  • the compound of the present invention can be used as the sole active ingredient, and can also be used in combination with other drugs for the treatment of diseases related to P2X3 activity. Combination therapy is achieved by administering the individual therapeutic components simultaneously, separately or sequentially.
  • alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably containing 1 to 6 carbons Atom of the alkyl group.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-Dimethylpropyl, 2,2-Dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2 -Methylhexyl, 3-methylhexyl, 4-methylhe
  • lower alkyl groups containing 1 to 6 carbon atoms More preferred are lower alkyl groups containing 1 to 6 carbon atoms.
  • Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, and sec-butyl.
  • Alkyl groups may be substituted or unsubstituted.
  • substituents When substituted, substituents may be substituted at any available attachment point.
  • the substituents are preferably one or more of the following groups, which are independently selected from alkanes Group, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkane An oxy group, a heterocycloalkoxy group, a cycloalkylthio group, a heterocycloalkylthio group, an oxo group, a carboxyl group or a carboxylate group.
  • alkenyl refers to an alkyl group as defined above composed of at least two carbon atoms and at least one carbon-carbon double bond, such as vinyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3 -Butenyl etc. Alkenyl groups may be substituted or unsubstituted.
  • the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio.
  • alkynyl refers to an alkyl group as defined above composed of at least two carbon atoms and at least one carbon-carbon triple bond, such as ethynyl, propynyl, butynyl, and the like.
  • the alkynyl group may be substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio.
  • cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent.
  • the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 6 Carbon atoms.
  • Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene Groups, cyclooctyl, etc.; polycyclic cycloalkyls include spiro, fused, and bridged cycloalkyls.
  • spirocycloalkyl refers to a polycyclic group that shares one carbon atom (called a spiro atom) between 5- to 20-membered monocyclic rings, which may contain one or more double bonds, but none of the rings have complete conjugate ⁇ electron system. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan.
  • the spirocycloalkyl group is classified into a single spirocycloalkyl group, a bispirocycloalkyl group or a polyspirocycloalkyl group, preferably a single spirocycloalkyl group and a bispirocycloalkyl group. More preferably, it is a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered monospirocycloalkyl.
  • spirocycloalkyl groups include:
  • fused cycloalkyl refers to a 5- to 20-membered all-carbon polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or Multiple double bonds, but none of the rings have a fully conjugated ⁇ -electron system. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan.
  • bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyls preferably bicyclic or tricyclic, and more preferably 5-membered/5-membered or 5-membered/6-membered bicyclic alkyl.
  • fused cycloalkyl groups include:
  • bridged cycloalkyl refers to a 5- to 20-membered, all-carbon polycyclic group with any two rings sharing two carbon atoms that are not directly connected. It may contain one or more double bonds, but no ring has a complete Conjugated ⁇ electron system. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of constituent rings, it can be classified into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyls, preferably bicyclic, tricyclic or tetracyclic, and more preferably bicyclic or tricyclic.
  • bridged cycloalkyl groups include:
  • the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl group, non-limiting examples include indanyl, tetrahydronaphthalene Group, benzocycloheptanyl group, etc. Cycloalkyl groups may be optionally substituted or unsubstituted.
  • the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, oxo, carboxy or carboxylate.
  • heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (where m is an integer of 0 to 2) heteroatoms, but does not include the ring part of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. It preferably contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; most preferably contains 3 to 8 ring atoms, of which 1 to 3 are heteroatoms; most preferably contains 5 to 7 ring atoms, of which 1 to 2 or 1 to 3 are heteroatoms.
  • Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidine Group, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl, etc., preferably 1, 2, 5-oxadiazolyl, pyranyl or morpholinyl.
  • Polycyclic heterocyclic groups include spiro, fused, and bridged heterocyclic groups.
  • spiroheterocyclic group refers to a polycyclic heterocyclic group that shares one atom (called a spiro atom) between 5- to 20-membered monocyclic rings, in which one or more ring atoms are selected from nitrogen, oxygen or S(O ) Heteroatoms of m (where m is an integer of 0 to 2), and the remaining ring atoms are carbon. It can contain one or more double bonds, but none of the rings have a fully conjugated ⁇ -electron system. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan.
  • the spiro heterocyclic group is classified into a single spiro heterocyclic group, a dispiro heterocyclic group or a polyspiro heterocyclic group, preferably a single spiro heterocyclic group and a dispiro heterocyclic group. More preferably, it is a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered monospiro heterocyclic group.
  • Non-limiting examples of spiroheterocyclic groups include:
  • fused heterocyclic group refers to a 5- to 20-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system.
  • One or more rings may contain one or more Double bond, but none of the rings have a fully conjugated ⁇ -electron system, where one or more of the ring atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), and the rest of the ring
  • the atom is carbon. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan.
  • bicyclic, tricyclic, tetracyclic or polycyclic condensed heterocyclic groups preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicyclic condensed heterocyclic group.
  • fused heterocyclic groups include:
  • bridged heterocyclic group refers to a 5- to 14-membered polycyclic heterocyclic group with any two rings sharing two atoms that are not directly connected. It may contain one or more double bonds, but none of the rings has a complete common A conjugated ⁇ -electron system in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen, or S(O) m (where m is an integer of 0 to 2), and the remaining ring atoms are carbon. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan.
  • bridged heterocyclic groups include:
  • the heterocyclic ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclic group, non-limiting examples of which include:
  • the heterocyclic group may be optionally substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, oxo, carboxy or carboxylate.
  • aryl refers to a 6 to 14-membered all-carbon monocyclic or fused polycyclic (that is, rings sharing adjacent pairs of carbon atoms) with a conjugated ⁇ -electron system, preferably 6 to 10 members, such as benzene Base and naphthyl. Phenyl is more preferred.
  • the aryl ring may be fused on a heteroaryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, non-limiting examples of which include:
  • the aryl group may be substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycle Alkylthio, carboxy, or carboxylate.
  • heteroaryl refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, where the heteroatoms are selected from oxygen, sulfur, and nitrogen.
  • Heteroaryl groups are preferably 5- to 10-membered, containing 1 to 3 heteroatoms; more preferably 5-membered or 6-membered, containing 1 to 2 heteroatoms; preferably, for example, imidazolyl, furyl, thienyl, thiazolyl, pyridine Azolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl, etc., preferably imidazolyl, thiazolyl, pyrazolyl or pyrimidinyl, thiazolyl; more preferably Pyrazolyl or thiazolyl.
  • the heteroaryl ring may be fused to an aryl, heterocyclic or cycl
  • Heteroaryl groups may be optionally substituted or unsubstituted.
  • the substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, carboxyl or carboxylate.
  • alkoxy refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), where the definition of alkyl is as described above.
  • alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
  • the alkoxy group may be optionally substituted or unsubstituted.
  • the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, carboxyl or carboxylate.
  • groups are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , Heterocycloalkylthio, carboxyl or carboxy
  • haloalkyl refers to an alkyl group substituted with one or more halogens, where the alkyl group is as defined above.
  • haloalkoxy refers to an alkoxy group substituted with one or more halogens, where alkoxy is as defined above.
  • hydroxyalkyl refers to an alkyl group substituted with a hydroxy group, where the alkyl group is as defined above.
  • hydroxy refers to the -OH group.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • amino refers to -NH 2 .
  • cyano refers to -CN.
  • nitro refers to -NO 2 .
  • mercapto refers to -SH.
  • ester group refers to -C(O)O (alkyl) or -C(O)O (cycloalkyl), where alkyl and cycloalkyl are as defined above.
  • acyl refers to a compound containing a -C(O)R group, where R is an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group, or a heteroaryl group.
  • sulfonic acid refers to -S(O) 2 OH.
  • sulfonate group refers to -S(O) 2 O (alkyl) or -S(O) 2 O (cycloalkyl), where alkyl and cycloalkyl are as defined above.
  • sulfonyl refers to a compound of the -S(O) 2 R group, where R is alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl.
  • aminoacyl refers to -C(O)-NRR', wherein R and R'are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl.
  • aminonosulfonyl or “sulfonylamino” refers to -S(O) 2 -NRR', wherein R and R'are each independently hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl base.
  • heterocyclic group optionally substituted by an alkyl group means that an alkyl group may but does not have to be present.
  • the description includes the case where the heterocyclic group is substituted by an alkyl group and the case where the heterocyclic group is not substituted by an alkyl group. .
  • Substituted refers to one or more hydrogen atoms in the group, preferably up to 5, more preferably 1 to 3 hydrogen atoms independently of each other substituted by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without too much effort. For example, an amino group or a hydroxyl group with free hydrogen may be unstable when combined with a carbon atom with an unsaturated (e.g., olefinic) bond.
  • “Pharmaceutical composition” means a mixture containing one or more of the compounds described herein or their physiologically/pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiological/pharmaceutically acceptable carriers And excipients.
  • the purpose of the pharmaceutical composition is to promote the administration to the organism, facilitate the absorption of the active ingredients and then exert the biological activity.
  • “Pharmaceutically acceptable salt” refers to the salt of the compound of the present invention, which is safe and effective when used in mammals, and has due biological activity.
  • the present invention adopts the following technical solutions.
  • Step 1 Reacting compound Ia with Ra (O) under acidic conditions and the presence of a reducing agent to obtain compound Ib, wherein the acidic reagent is preferably acetic acid, and the reducing agent is preferably sodium cyanoborohydride;
  • Step 2 Under alkaline conditions, reacting compound Ib with R b I to obtain compound Ic, wherein the alkaline reagent is preferably NaH;
  • Step 3 In the presence of high temperature, alkalinity and catalyst, compound Ic is reacted with pinacol diboronic acid to obtain compound Id, wherein the high temperature condition is preferably 100°C, the alkaline reagent is preferably potassium acetate, and the catalyst is preferably Pd(dppf) Cl 2 catalyst;
  • Step 4 In the presence of high temperature, alkalinity and catalyst, compound Id is reacted with compound Ie to obtain compound If, wherein the high temperature condition is preferably 90°C, the alkaline reagent is preferably potassium carbonate, and the catalyst is preferably Pd(dppf)Cl 2 catalyst;
  • Step 5 Under alkaline conditions, hydrolyze compound If to obtain compound Ig, wherein the alkaline reagent is preferably lithium hydroxide;
  • Step 6 In the presence of a condensing agent, the compound Ig and Ih are subjected to a condensation reaction under basic conditions to obtain a compound of general formula (I), wherein the basic condition is preferably DIPEA, and the condensing agent is preferably HATU.
  • the basic condition is preferably DIPEA
  • the condensing agent is preferably HATU.
  • Step 1 The compound Ii is reacted with (4-methoxyphenyl)methanethiol in the presence of high temperature, basicity and a catalyst to obtain compound Ij, wherein the high temperature condition is preferably 100°C, the alkaline reagent is preferably DIPEA, and the catalyst is preferably Pd 2 (dba) 3 and Xantphos;
  • the high temperature condition is preferably 100°C
  • the alkaline reagent is preferably DIPEA
  • the catalyst is preferably Pd 2 (dba) 3 and Xantphos
  • Step 2 In the presence of high temperature, alkalinity and catalyst, compound Ij is reacted with pinacol diboronic acid ester to obtain compound Ik, wherein the high temperature condition is preferably 100°C, the alkaline reagent is preferably potassium acetate, and the catalyst is preferably Pd(dppf) Cl 2 ;
  • Step 3 In the presence of high temperature, alkalinity and catalyst, compound Ik is reacted with compound Ie to obtain compound Il, wherein the high temperature condition is preferably 90°C, the alkaline reagent is preferably potassium carbonate, and the catalyst is preferably Pd(dppf)Cl 2 ;
  • Step 4 In the presence of a low temperature and an oxidizing agent, the compound 11 is reacted to obtain the compound Im, wherein the low temperature condition is preferably -15°C, and the oxidizing agent is preferably 1,3-dichloro-5,5-dimethylhydantoin (DCDMH);
  • DCDMH 1,3-dichloro-5,5-dimethylhydantoin
  • Step 5 under basic conditions, with Im HR a compound obtained by reacting a compound of In, wherein the alkaline reagent is preferably sodium carbonate;
  • Step 6 Under alkaline conditions, hydrolyze compound In to obtain compound Io, wherein the alkaline reagent is preferably lithium hydroxide;
  • Step 7 In the presence of a condensing agent, the compound Io and Ih are subjected to a condensation reaction under basic conditions to obtain a compound of general formula (I), wherein the basic condition is preferably DIPEA, and the condensing agent is preferably HATU.
  • the basic condition is preferably DIPEA
  • the condensing agent is preferably HATU.
  • Step 1 Under alkaline conditions, reacting compound Im with HNR a R b to obtain compound Ip, wherein the alkaline reagent is preferably sodium carbonate;
  • Step 2 Under alkaline conditions, the compound Ip is hydrolyzed to obtain the compound Iq, wherein the alkaline reagent is preferably lithium hydroxide;
  • Step 3 In the presence of a condensing agent, the compound Iq and Ih are subjected to a condensation reaction under basic conditions to obtain a compound of general formula (I), wherein the basic condition is preferably DIPEA, and the condensing agent is preferably HATU.
  • the basic condition is preferably DIPEA
  • the condensing agent is preferably HATU.
  • Step 1 In the presence of high temperature, alkalinity and catalyst, compound Ir is reacted with HP(O)R a R b to obtain compound Is, wherein the high temperature condition is preferably 65°C, the alkaline reagent is preferably potassium phosphate, and the catalyst is preferably Pd(OAc ) 2 and Xantphos;
  • Step 2 In the presence of high temperature, alkalinity and catalyst, compound Is is reacted with diboronic acid pinacol ester to obtain compound It, wherein the high temperature condition is preferably 100°C, the alkaline reagent is preferably potassium acetate, and the catalyst is preferably Pd(dppf) Cl 2 ;
  • Step 3 In the presence of high temperature, alkalinity and catalyst, compound It and Ie are reacted to obtain compound Iu, wherein the high temperature condition is preferably 90°C, the alkaline reagent is preferably potassium carbonate, and the catalyst is preferably Pd(dppf)Cl 2 ;
  • Step 4 Under alkaline conditions, hydrolyze compound Iu to obtain compound Iv, wherein the alkaline reagent is preferably lithium hydroxide;
  • Step 5 In the presence of a condensing agent, the compound Iv and Ih are subjected to a condensation reaction under basic conditions to obtain a compound of general formula (I), wherein the basic condition is preferably DIPEA, and the condensing agent is preferably HATU.
  • the basic condition is preferably DIPEA
  • the condensing agent is preferably HATU.
  • W 1 , W 2 , W 3 , A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , R 2 , R 3 , and L are as defined in the general formula (I).
  • the structure of the compound is determined by nuclear magnetic resonance (NMR) or/and mass spectrometry (MS). NMR shifts are given in units of 10 -6 (ppm). NMR is measured by Brukerdps300 nuclear magnetometer, the solvent is deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl 3 ), deuterated methanol (CD 3 OD), and the internal standard is tetramethyl Silane (TMS).
  • DMSO-d 6 dimethyl sulfoxide
  • CDCl 3 deuterated chloroform
  • CD 3 OD deuterated methanol
  • TMS tetramethyl Silane
  • GC-MS measurement uses GCMS-QP2010SE.
  • the lc3000 high performance liquid chromatograph and lc6000 high performance liquid chromatograph are used for the preparation of the liquid phase.
  • the chromatographic column is Daisogel C18 10 ⁇ m 60A (20mm ⁇ 250mm).
  • HPLC determination uses Shimadzu LC-20AD high pressure liquid chromatograph (Agilent TC-C18 250 ⁇ 4.6mm 5 ⁇ m column) and Shimadzu LC-2010AHT high pressure liquid chromatograph (Phenomenex C18 250 ⁇ 4.6mm 5 ⁇ m column).
  • the thin layer chromatography silica gel plate uses Qingdao Ocean Chemical GF254 silica gel plate, the size of the silica gel plate used in thin layer chromatography (TLC) is 0.15mm ⁇ 0.2mm, and the size of thin layer chromatography separation and purification products is 0.4mm ⁇ 0.5 mm.
  • the known starting materials of the present invention can be synthesized by or according to methods known in the art, or can be purchased from the network shopping mall, Beijing Coupling, Sigma, Bailingwei, Yi Shiming, Shanghai Shuya, Inokia, Nanjing Yaoshi, Anaiji Chemical and other companies.
  • reaction can all be carried out under an argon atmosphere or a nitrogen atmosphere.
  • the argon atmosphere or nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon with a volume of about 1L.
  • the microwave reaction uses CEM Discover SP type microwave reactor.
  • the solution refers to an aqueous solution.
  • reaction temperature is room temperature, which is 20°C to 30°C.
  • the monitoring of the reaction progress in the examples adopts thin-layer chromatography (TLC).
  • the developing reagent system used in the reaction includes: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether And ethyl acetate system, D: acetone, the volume ratio of the solvent is adjusted according to the polarity of the compound.
  • the eluent system of column chromatography and the developing solvent system of thin layer chromatography used to purify compounds include: A: dichloromethane and methanol system, B: petroleum ether, ethyl acetate and dichloromethane system, C: petroleum In the ether and ethyl acetate system, the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of basic or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.
  • Step 4 Synthesis of methyl 3-(methyl(oxetan-3-yl)amino)-5-(5-methylthiazol-2-yl)benzoate (1e)
  • reaction solution was concentrated under reduced pressure, and the residue was extracted with 50 mL of ethyl acetate and 50 mL of water.
  • the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
  • Step 6 (R)-3-(Methyl(oxetan-3-yl)amino)-5-(5-methylthiazol-2-yl)-N-(1-(2-(tri Synthesis of (fluoromethyl)pyrimidin-5-yl)ethyl)benzamide (compound 1)
  • Step 3 Synthesis of methyl 3-((4-methoxybenzyl)thio)-5-(5-methylthiazol-2-yl)benzoate (2d)
  • reaction solution was filtered, and 100 mL of ethyl acetate and 100 mL of water were added to the filtrate for extraction.
  • the organic phase was washed once with water, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
  • Step 4 Synthesis of methyl 3-(chlorosulfonyl)-5-(5-methylthiazol-2-yl)benzoate (2e)
  • Step 5 Synthesis of methyl 3-(5-methylthiazol-2-yl)-5-(pyrrolidin-1-ylsulfonyl)benzoate (2f)
  • Step 7 (R)-3-(5-Methylthiazol-2-yl)-5-(pyrrolidin-1-ylsulfonyl)-N-(1-(2-(trifluoromethyl)pyrimidine- Synthesis of 5-yl)ethyl)benzamide (compound 2)
  • reaction solution was poured into 100 mL ice water, stirred for 10 minutes, filtered, and the filter cake was passed through preparative liquid chromatography (column: Hedea ODS-2 C18, 300mm*250mm, 10 ⁇ m; eluent: 0%- 100% acetonitrile: aqueous solution) to obtain 107 mg of the title product as a white solid, yield: 51.2%.
  • the preparation method was the same as in Example 2, except that ammonia water was used instead of tetrahydropyrrole to obtain the title compound 3.
  • the preparation method was the same as in Example 2, except that cyclopropylamine was used instead of tetrahydropyrrole to obtain the title compound 5.
  • reaction solution was concentrated under reduced pressure, 50 mL of ethyl acetate and 50 mL of water were added to the residue for extraction, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure.
  • Step 1 (R)-3-(Methyl(piperidin-4-yl)amino)-5-(5-methylthiazol-2-yl)-N-(1-(2-(trifluoromethyl) )Pyrimidine-5-yl)ethyl)benzamide (Compound 7)
  • the preparation method is the same as that of Example 1, except that N-tert-butoxycarbonyl-4-piperidone is used instead of oxetan-3-one to prepare Intermediate 7a.
  • Step 4 (R)-3-(3-methyl-1H-pyrazol-1-yl)-5-(oxetan-3-yloxy)-N-(1-(2-( Synthesis of trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (compound 9)
  • the preparation method was the same as in Example 2, except that 4,4-difluoropiperidine was used instead of tetrahydropyrrole to obtain the title compound 10.
  • Test Example 1 Evaluation of the compound of the present invention on the inhibitory activity of human P2X3 receptors
  • Fluorescence Image Plate Reader (FLIPR, Molecular Devices, 0296) was used to monitor changes in intracellular calcium levels to evaluate the inhibitory activity of the compounds of the present invention on human P2X3 receptors.
  • trypsin (Thermofisher, 12604021) digests the cells and resuspends them in cell seeding medium (DMEM, high glucose ( 31053028, Gibco) + 2% Fetal Bovine Serum (FBS) (Gibco, 10099141) + 4mM GlutaMAX (Gibco, 35050-061)), inoculate 11000 cells/well/25 ⁇ L to a 384-well cell culture plate (Corning, 3845) Component A powder (FLIPR Calcium 6 Assay Kit) was incubated in an incubator at 37°C and 5% CO 2 for 22 hours.
  • DMEM high glucose
  • FBS Fetal Bovine Serum
  • GlutaMAX GlutaMAX
  • the cell culture plate is allowed to stand at room temperature for 10 minutes, and the working solution of the compound to be tested (the initial concentration of detection is 10000 nM, and the cell seeding medium is used to dilute 3 times so that the final concentration of DMSO is 0.1%) is added to the corresponding 384-well cell culture plate Incubate the experimental wells at room temperature for 30 minutes.
  • Use FLIPR Tetra (Molecular Devices, 0296) to add 10 ⁇ L of diluted ⁇ , ⁇ -MeATP to the corresponding experimental wells to be tested, set the excitation wavelength to 470-495nm and the emission wavelength to 515- Detect the fluorescence value at 575nm and collect the data.
  • the inhibitory activity of the compounds of the present invention on P2X3 receptors is shown in Table 1 below.
  • the compound of the present invention inhibits the IC 50 value of P2X3 receptor
  • Test Example 2 Evaluation of the compound of the present invention on the inhibitory activity of human P2X2/3 receptor
  • the FLIPR method was used to monitor changes in intracellular calcium levels to evaluate the inhibitory activity of the compounds of the present invention on human P2X2/3 receptors.
  • the HEK293/hP2X2/3 cell line (Bioduro clone#164) was resuscitated, and the cells were seeded in a 384-well plate coated with 5 ⁇ L/well of 1X Matrigel (BD Bioscience, 354230). Incubate for 30 minutes in a 37°C, 5% CO 2 incubator. Then process the cells, remove the culture medium, wash once with PBS, digest the cells with 0.25% trypsin-EDTA (Invitrogen, 25200056), and adjust the cell density to 7.5 ⁇ 10 5 /mL. Add the diluted cells to a 384-well detection plate (Corning, 3709), 20 ⁇ L/well.
  • the inhibitory activity of the compounds of the present invention on P2X2/3 receptors is shown in Table 2 below.
  • the compound of the present invention inhibits the IC 50 value of P2X2/3 receptor
  • the compound of the present invention has poor inhibitory activity on P2X2/3 heterodimeric receptors.
  • Test Example 3 Pharmacokinetic properties of the compound of the present invention
  • the oral dosage of the compound of Example 6 and Example 12 was 3 mg/kg, and the blood sampling point was determined to be 8 minutes, 15 minutes, 30 minutes, 1 hour, 3 hours, 5 hours, 8 minutes before oral administration and after administration. Hours, 10 hours, 12 hours and 24 hours. Animals were anesthetized by inhalation, anesthesia parameters: flow rate: 1.0 L/m, oxygen pressure: 0.1 MPa, solubility: 4.5%, anesthesia time: 3 minutes. After the animal was anesthetized, 0.5 mL of blood was collected from the orbit, and the blood collection tube was added at a volume ratio of 10 mg/mL lithium heparin to plasma at a volume ratio of 1:10 for anticoagulation. After mixing uniformly, centrifuge at 3000 rpm/centrifuge for 10 minutes, take the upper layer of plasma, and freeze it in a refrigerator at -20°C for later use.
  • DAS was used for statistical analysis. Obtain various pharmacokinetic parameters and drug-time curves.
  • Test Example 4 Efficacy of the compound of the present invention on histamine-citrate guinea pig acute cough model
  • mice were grouped into a model control group, a 3 mg/kg administration group of the compound of Example 6 and a 30 mg/kg administration group of the compound of Example 6. 30-60 minutes before stimulating guinea pigs to cough, each group was given corresponding drugs. First, use 2mg/mL histamine solution ultrasonic atomization inhalation to the allergic guinea pig for 1-2 minutes, and quickly take it out after coughing.
  • Example 6 can effectively prolong the incubation period of cough in guinea pigs, significantly reduce the number of coughs, and has the value of further development.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé arylformamide et son procédé de préparation et son utilisation médicale. En particulier, la présente invention concerne un composé représenté dans la formule générale (I), son procédé de préparation, une composition pharmaceutique contenant le composé et son utilisation en tant qu'antagoniste du récepteur P2X3. Le composé et la composition pharmaceutique contenant le composé peuvent être utilisés pour traiter et/ou prévenir des maladies liées à l'activité de P2X3, tels que la toux chronique, la douleur, l'endométriose, la vessie hyperactive, etc. La définition de chaque substituant dans la formule générale (I) est la même que celle dans la description.
PCT/CN2021/095424 2020-05-25 2021-05-24 Composé arylformamide et son procédé de préparation et son utilisation médicale WO2021238834A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021282039A AU2021282039A1 (en) 2020-05-25 2021-05-24 Arylformamide compound and preparation method and medical use thereof
CN202180004411.6A CN114072399A (zh) 2020-05-25 2021-05-24 芳甲酰胺类化合物及其制备方法和医药用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010447193 2020-05-25
CN202010447193.0 2020-05-25

Publications (1)

Publication Number Publication Date
WO2021238834A1 true WO2021238834A1 (fr) 2021-12-02

Family

ID=78745622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/095424 WO2021238834A1 (fr) 2020-05-25 2021-05-24 Composé arylformamide et son procédé de préparation et son utilisation médicale

Country Status (4)

Country Link
CN (1) CN114072399A (fr)
AU (1) AU2021282039A1 (fr)
TW (1) TW202144342A (fr)
WO (1) WO2021238834A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022199654A1 (fr) * 2021-03-24 2022-09-29 Chengdu Anticancer Bioscience, Ltd. Composés hétéroaryle-hétéroaryl-o-phényle, compositions et méthodes de traitement de troubles cancéreux

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574778A (zh) * 2009-06-22 2012-07-11 弗·哈夫曼-拉罗切有限公司 新的联苯基和苯基-吡啶酰胺类化合物
US20170056398A1 (en) * 2009-06-22 2017-03-02 Roche Palo Alto Llc Substituted pyridines as p2x3 and p2x2/3 antagonists
US20170081320A1 (en) * 2008-12-16 2017-03-23 Roche Palo Alto Llc Thiadiazole-substituted arylamides as p2x3 and p2x2/3 antagonists
CN107207507A (zh) * 2014-12-09 2017-09-26 拜耳公司 1,3‑噻唑‑2‑基取代的苯甲酰胺
WO2019219672A1 (fr) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
WO2019219674A1 (fr) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses
WO2020260463A1 (fr) * 2019-06-27 2020-12-30 Bayer Aktiengesellschaft Analogues de3-(5-méthyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}benzamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP285898A0 (en) * 1998-04-07 1998-04-30 Fujisawa Pharmaceutical Co., Ltd. Amido derivatives
WO2009058298A1 (fr) * 2007-10-31 2009-05-07 Merck & Co., Inc. Antagonistes du récepteur p2x3 utilisés dans le traitement de la douleur
CN101981003B (zh) * 2008-02-29 2014-07-02 伊沃泰克股份公司 酰胺化合物、组合物及其应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170081320A1 (en) * 2008-12-16 2017-03-23 Roche Palo Alto Llc Thiadiazole-substituted arylamides as p2x3 and p2x2/3 antagonists
CN102574778A (zh) * 2009-06-22 2012-07-11 弗·哈夫曼-拉罗切有限公司 新的联苯基和苯基-吡啶酰胺类化合物
US20150080408A1 (en) * 2009-06-22 2015-03-19 Roche Palo Alto Llc Pyridinyl amides as p2x3 and p2x2/3 inhibitors
US20170056398A1 (en) * 2009-06-22 2017-03-02 Roche Palo Alto Llc Substituted pyridines as p2x3 and p2x2/3 antagonists
US20170057932A1 (en) * 2009-06-22 2017-03-02 Roche Palo Alto Llc Biphenyl and phenyl-pyridine amides as p2x3 and p2x2/3 antagonists
CN107207507A (zh) * 2014-12-09 2017-09-26 拜耳公司 1,3‑噻唑‑2‑基取代的苯甲酰胺
WO2019219672A1 (fr) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
WO2019219674A1 (fr) * 2018-05-15 2019-11-21 Bayer Aktiengesellschaft Benzamides substitués par 1,3-thiazol-2-yle pour le traitement de maladies associées à la sensibilisation des fibres nerveuses
WO2020260463A1 (fr) * 2019-06-27 2020-12-30 Bayer Aktiengesellschaft Analogues de3-(5-méthyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-méthyl)pyrimidin-5-yl]éthyl}benzamide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022199654A1 (fr) * 2021-03-24 2022-09-29 Chengdu Anticancer Bioscience, Ltd. Composés hétéroaryle-hétéroaryl-o-phényle, compositions et méthodes de traitement de troubles cancéreux

Also Published As

Publication number Publication date
AU2021282039A1 (en) 2022-12-01
TW202144342A (zh) 2021-12-01
CN114072399A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
TWI718207B (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
JP7050751B2 (ja) Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
TWI642667B (zh) 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用
CN110088105B (zh) Jak家族激酶的小分子抑制剂
TW202115076A (zh) 嘧啶并五員氮雜環類衍生物、其製備方法及其在醫藥上的應用
WO2021027911A1 (fr) Nouvel inhibiteur de k-ras g12c spirocyclique
EP3610874A1 (fr) Composition pharmaceutique contenant un agoniste du mor et un agoniste du kor, et ses utilisations
TW202043200A (zh) ２－側氧基－１，２－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
CN110072865B (zh) 吡咯并芳杂环类化合物及其制备方法和医药用途
CN103097340A (zh) 治疗活性组合物及其使用方法
TW202012412A (zh) 一種含有醯胺類衍生物的醫藥組成物及其製備方法和應用
TWI718113B (zh) 吡啶甲醯胺類衍生物、其製備方法及其在醫藥上的應用
CN107033097B (zh) 噁二唑类衍生物、其制备方法及其在医药上的应用
WO2011136269A1 (fr) Composé de tétrahydrobenzothiophène
EP3919489A1 (fr) Composés cycliques aromatiques ou cycliques hétéroaromatiques, procédé de préparation correspondant et utilisation médicale associée
WO2020011146A1 (fr) Composés 1,2,4-oxadiazole, leur procédé de préparation et utilisation médicale associée
TW202102480A (zh) ６－側氧基－１，６－二氫噠嗪類前藥衍生物、其製備方法及其在醫藥上的應用
TW200304817A (en) Chemical compounds
WO2019154294A1 (fr) Dérivé de pyrazolo[1,5-a][1,3,5]triazine-2-amine, son procédé de préparation et son utilisation médicale
CN110167941A (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
WO2021238834A1 (fr) Composé arylformamide et son procédé de préparation et son utilisation médicale
TW202214603A (zh) 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用
WO2019052440A1 (fr) Dérivé d'indole-formamide substitué par un atome de deutérium, son procédé de préparation et ses applications médicales
WO2021088920A1 (fr) Régulateur de dérivé de benzothiophène, son procédé de préparation et son utilisation
TW202128693A (zh) 含吡唑多環類衍生物抑制劑、其製備方法和應用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21812122

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021282039

Country of ref document: AU

Date of ref document: 20210524

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21812122

Country of ref document: EP

Kind code of ref document: A1